iCAD, Inc. (NASDAQ:ICAD) Given Consensus Rating of “Moderate Buy” by Analysts

iCAD, Inc. (NASDAQ:ICADGet Rating) has earned an average rating of “Moderate Buy” from the seven research firms that are presently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $8.60.

Several research firms recently commented on ICAD. BTIG Research decreased their price target on shares of iCAD to $6.00 in a research note on Monday, August 15th. JMP Securities reduced their price objective on shares of iCAD from $13.00 to $7.00 and set a “market outperform” rating on the stock in a research note on Thursday, September 1st. Lake Street Capital reduced their price objective on shares of iCAD from $13.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, August 11th. Finally, Craig Hallum reduced their price objective on shares of iCAD to $6.00 in a research note on Monday, August 15th.

iCAD Price Performance

NASDAQ:ICAD opened at $2.35 on Friday. iCAD has a one year low of $2.00 and a one year high of $12.60. The company has a market cap of $59.53 million, a P/E ratio of -4.52 and a beta of 1.13. The firm’s fifty day moving average price is $3.24 and its two-hundred day moving average price is $3.68.

Insiders Place Their Bets

In other iCAD news, CTO Jonathan Go sold 38,960 shares of the firm’s stock in a transaction that occurred on Monday, September 12th. The shares were sold at an average price of $2.74, for a total transaction of $106,750.40. Following the completion of the transaction, the chief technology officer now owns 188,725 shares in the company, valued at approximately $517,106.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 12.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Rhumbline Advisers grew its position in shares of iCAD by 26.9% during the 1st quarter. Rhumbline Advisers now owns 19,635 shares of the technology company’s stock worth $88,000 after buying an additional 4,159 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of iCAD by 7.6% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 60,038 shares of the technology company’s stock worth $268,000 after buying an additional 4,253 shares during the period. Essex Investment Management Co. LLC grew its position in shares of iCAD by 4.8% during the 1st quarter. Essex Investment Management Co. LLC now owns 122,011 shares of the technology company’s stock worth $544,000 after buying an additional 5,639 shares during the period. Raymond James & Associates grew its position in shares of iCAD by 62.1% during the 1st quarter. Raymond James & Associates now owns 21,750 shares of the technology company’s stock worth $97,000 after buying an additional 8,331 shares during the period. Finally, Bank of Montreal Can acquired a new stake in shares of iCAD during the 2nd quarter worth approximately $46,000. Institutional investors own 52.68% of the company’s stock.

iCAD Company Profile

(Get Rating)

iCAD, Inc provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment.

Read More

Analyst Recommendations for iCAD (NASDAQ:ICAD)

Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.